Aptevo Therapeutics Files 8-K: Material Agreement

TL;DR

APVO filed an 8-K on 4/10 for a material definitive agreement. Details TBD.

AI Summary

On April 10, 2024, Aptevo Therapeutics Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. Specific details of the agreement and financial information were not provided in the excerpt.

Why It Matters

This filing indicates a significant new agreement for Aptevo Therapeutics, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in the provided text necessitates a medium risk assessment.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• April 10, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
• $1.35 — mon Stock at a public offering price of $1.35 per share and accompanying Common Warra
• $1.3499 — at a combined public offering price of $1.3499 per Pre-funded Warrant and accompanying
• $0.0001 — nd accompanying Common Warrant less the $0.0001 per share exercise price of each such P
• $4.0 million — received net proceeds of approximately $4.0 million from the Offering, after deducting the

Filing Documents

• apvo-20240410.htm (8-K) — 52KB
• apvo-ex4_1.htm (EX-4.1) — 155KB
• apvo-ex4_2.htm (EX-4.2) — 152KB
• apvo-ex10_1.htm (EX-10.1) — 155KB
• apvo-ex10_2.htm (EX-10.2) — 313KB
• apvo-ex99_1.htm (EX-99.1) — 15KB
• apvo-ex99_2.htm (EX-99.2) — 13KB
• img237228349_0.jpg (GRAPHIC) — 4KB
• img238151870_0.jpg (GRAPHIC) — 4KB
• 0000950170-24-044419.txt ( ) — 1127KB
• apvo-20240410.xsd (EX-101.SCH) — 25KB
• apvo-20240410_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. The information regarding the Purchase Agreements (as defined below) set forth in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

01 Other Events

Item 8.01 Other Events. On April 10, 2024, Aptevo Therapeutics Inc. (the "Company") priced a best efforts public offering (the "Offering") of: (i) 926,666 shares of its common stock, par value $0.001 per share ("Common Stock") and accompanying common warrants ("Common Warrants") to purchase up to 1,853,332 shares of Common Stock at a public offering price of $1.35 per share and accompanying Common Warrants and (ii) pre-funded warrants ("Pre-funded Warrants") to purchase 2,473,334 shares of Common Stock and accompanying Common Warrants to purchase up to 4,946,668 shares of Common Stock at a combined public offering price of $1.3499 per Pre-funded Warrant and accompanying Common Warrants, which is equal to the public offering price per share of Common Stock and accompanying Common Warrant less the $0.0001 per share exercise price of each such Pre-funded Warrant. The Common Warrants have an exercise price of $1.35 per share of Common Stock. The Common Warrants are exercisable upon issuance and will expire five years from the date of issuance. The exercise price of the Common Warrants is subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in the Common Warrants. In connection with the Offering, the Company entered into a Placement Agent Agreement on April 10, 2024 with Roth Capital Partners, LLC (the "Placement Agent"), as the exclusive placement agent in connection with the Offering. Dawson James Securities, Inc. acted as co-agent. As compensation to the Placement Agent, the Company paid the Placement Agent a cash fee of 7.0% of the aggregate gross proceeds raised in the Offering, and reimbursement of certain expenses. In connecti

01 Other Events

Item 8.01 Other Events The Company issued press releases announcing the Offering and the closing of the Offering on April 10, 2024 and April 15, 2024, respectively. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 4.1 Common Warrant, dated April 15, 2024. 4.2 Pre-funded Warrant, dated April 15, 2024. 10.1 Placement Agent Agreement, dated April 10, 2024, between the Company and Roth Capital Partners. 10.2 Securities Purchase Agreement, dated April 10, 2024, between the Company and the purchasers party thereto. 99.1 Press Release, dated April 11, 2024. 99.2 Press Release, dated April 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: April 15, 2024 By: /s/ Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR